Amgen takes the issue of counterfeit drugs very seriously and is committed to the highest standards of drug quality and patient safety. Counterfeits by their nature are of unknown safety and efficacy, thereby putting patients at risk.
Our brand protection program supports an effective, secure, and resilient global supply chain, and the overall integrity of Amgen’s medicines, for the protection and safety of our patients. Some of the measures Amgen is employing to deter, detect, and disrupt the criminal counterfeiting of our medicines include